344 related articles for article (PubMed ID: 11531279)
1. Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients.
Alvarez AA; Axelrod JR; Whitaker RS; Isner PD; Bentley RC; Dodge RK; Rodriguez GC
Gynecol Oncol; 2001 Aug; 82(2):273-8. PubMed ID: 11531279
[TBL] [Abstract][Full Text] [Related]
2. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
[TBL] [Abstract][Full Text] [Related]
3. Cathepsin D in ovarian cancer: prognostic value and correlation with p53 expression and microvessel density.
Lösch A; Schindl M; Kohlberger P; Lahodny J; Breitenecker G; Horvat R; Birner P
Gynecol Oncol; 2004 Feb; 92(2):545-52. PubMed ID: 14766246
[TBL] [Abstract][Full Text] [Related]
4. Thrombospondins I and II messenger RNA expression in lung carcinoma: relationship with p53 alterations, angiogenic growth factors, and vascular density.
Fontanini G; Boldrini L; Calcinai A; Chinè S; Lucchi M; Mussi A; Angeletti CA; Basolo F; Bevilacqua G
Clin Cancer Res; 1999 Jan; 5(1):155-61. PubMed ID: 9918214
[TBL] [Abstract][Full Text] [Related]
5. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
Laframboise S; Chapman W; McLaughlin J; Andrulis IL
Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of KAI1 metastasis suppressor protein is associated with a dismal prognosis in epithelial ovarian cancer.
Schindl M; Birner P; Breitenecker G; Oberhuber G
Gynecol Oncol; 2001 Nov; 83(2):244-8. PubMed ID: 11606078
[TBL] [Abstract][Full Text] [Related]
7. Association of angiogenesis markers with lymph node metastasis in early colorectal cancer.
Iddings DM; Koda EA; Grewal SS; Parker R; Saha S; Bilchik A
Arch Surg; 2007 Aug; 142(8):738-44; discussion 744-5. PubMed ID: 17709727
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of thrombospondin-1 expression in relation to vascular endothelial growth factor and interleukin-10 expression at the deepest invasive tumor site of advanced colorectal carcinoma.
Kaio E; Tanaka S; Oka S; Hiyama T; Kitadai Y; Haruma K; Chayama K
Int J Oncol; 2003 Oct; 23(4):901-11. PubMed ID: 12963968
[TBL] [Abstract][Full Text] [Related]
9. p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer.
Eltabbakh GH; Belinson JL; Kennedy AW; Biscotti CV; Casey G; Tubbs RR; Blumenson LE
Cancer; 1997 Sep; 80(5):892-8. PubMed ID: 9307189
[TBL] [Abstract][Full Text] [Related]
10. The expression of thrombospondin-1 and p53 in clear cell renal cell carcinoma: its relationship to angiogenesis, cell proliferation and cancer specific survival.
Zubac DP; Bostad L; Kihl B; Seidal T; Wentzel-Larsen T; Haukaas SA
J Urol; 2009 Nov; 182(5):2144-9. PubMed ID: 19758660
[TBL] [Abstract][Full Text] [Related]
11. Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study.
; Secord AA; Lee PS; Darcy KM; Havrilesky LJ; Grace LA; Marks JR; Berchuck A
Gynecol Oncol; 2006 Jun; 101(3):390-7. PubMed ID: 16551475
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic value of microvessel density and angiogenesis-related molecules in epithelial ovarian cancer].
Tan XJ; Lang JH; Lou WZ; Shen K; Xu XY
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):274-8. PubMed ID: 18788631
[TBL] [Abstract][Full Text] [Related]
13. The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer.
Goodheart MJ; Ritchie JM; Rose SL; Fruehauf JP; De Young BR; Buller RE
Clin Cancer Res; 2005 May; 11(10):3733-42. PubMed ID: 15897570
[TBL] [Abstract][Full Text] [Related]
14. Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study.
Secord AA; Darcy KM; Hutson A; Lee PS; Havrilesky LJ; Grace LA; Berchuck A;
Gynecol Oncol; 2007 Jul; 106(1):221-32. PubMed ID: 17481705
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of HER-2, p53 and Bcl-2 in patients with epithelial ovarian cancer.
Malamou-Mitsi V; Crikoni O; Timotheadou E; Aravantinos G; Vrettou E; Agnantis N; Fountzilas G
Anticancer Res; 2007; 27(2):1157-65. PubMed ID: 17465257
[TBL] [Abstract][Full Text] [Related]
16. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
17. P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome.
Gadducci A; Di Cristofano C; Zavaglia M; Giusti L; Menicagli M; Cosio S; Naccarato AG; Genazzani AR; Bevilacqua G; Cavazzana AO
Anticancer Res; 2006; 26(1B):687-93. PubMed ID: 16739339
[TBL] [Abstract][Full Text] [Related]
18. [Predictive value of P53 expression in selecting first-line chemotherapy regimen for advanced epithelial ovarian carcinoma].
Zhao XD; Zhang Y; He SR; Yang L
Ai Zheng; 2005 Dec; 24(12):1542-5. PubMed ID: 16351810
[TBL] [Abstract][Full Text] [Related]
19. Thrombospondin-1 expression in relation to p53 status and VEGF expression in human breast cancers.
Linderholm B; Karlsson E; Klaar S; Lindahl T; Borg AL; Elmberger G; Bergh J
Eur J Cancer; 2004 Nov; 40(16):2417-23. PubMed ID: 15519514
[TBL] [Abstract][Full Text] [Related]
20. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.
Righetti SC; Della Torre G; Pilotti S; Ménard S; Ottone F; Colnaghi MI; Pierotti MA; Lavarino C; Cornarotti M; Oriana S; Böhm S; Bresciani GL; Spatti G; Zunino F
Cancer Res; 1996 Feb; 56(4):689-93. PubMed ID: 8630996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
